3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
14
Neoplasm Metastasis
9
Stomach Neoplasms
5
Endometrial Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Adenocarcinoma
3
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Advanced Breast Cancer
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Interventions
fludarabine
3
aldesleukin
3
Specimen Handling
3
Fluorouracil
3
Cyclophosphamide
3
Bevacizumab
3
Sunitinib
2
Leucovorin
2
trastuzumab deruxtecan
1
sodium propionate
1
semaglutide
1
repotrectinib
1
patritumab deruxtecan
1
isosorbide-5-mononitrate
1
fludarabine phosphate
1
dehydroftorafur
1
Ultrasonography
1
Tretinoin
1
Tomography, X-Ray Computed
1
Surveys and Questionnaires
1
Radiosurgery
1
Psilocybin
1
Positron-Emission Tomography
1
Photography
1
Pemetrexed
1
Pafolacianine
1
Oxaliplatin
1
Oviposition
1
Memantine
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
trastuzumab deruxtecan
×
30 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled